on MEDINCELL (EPA:MEDCL)
Medincell: Key Results and Initiatives for 2025-2026
Medincell has published its financial results for the 2025-2026 fiscal year, marking a significant transition to a business model supported by innovative products. Revenue reached €24.3 million, with a substantial contribution of €9.3 million in royalties from UZEDY®. Operating investments increased by 17%, reaching €45 million, to support future growth. Cash flow strengthened, peaking at €84.8 million thanks to a significant fundraising round.
Medincell continues to expand its development portfolio with notable advancements, including Olanzapine LAI, which is slated for launch in the United States in late 2026, subject to regulatory approvals. The partnership with AbbVie and ongoing R&D initiatives are contributing to the growth of their pipeline.
The strengthening of governance, with the arrival of new directors, and the expansion of the technology platform, support Medincell's long-term strategy aimed at high-margin recurring revenues.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news